🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

164 results for “Janssen” Clear

  1. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  2. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  3. PREDNISONE, PREDNISONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Imaavy 185 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

    phase 3 small molecule active

    1 trial

  4. Placebo Film-coated tablet, JNJ-42847922

    Janssen-Cilag International N.V.

    Major Depressive Disorder with Insomnia Symptoms

    phase 3 small molecule active

    1 trial

  5. Placebo JNJ-78278343, Placebo JNJ-78278343, JNJ-78278343, JNJ-78278343

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  6. Placebo for Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  7. Placebo to Guselkumab Solution for injection in pre-filled syringe 100 mg/ml., Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  8. Pomalidomide, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, BORTEZOMIB, Imnovid 2 mg hard capsules, FLUDARABINE , CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Pomalidomide, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Imnovid 1 mg hard capsules, CYCLOPHOSPHAMIDE , Dexamethason 4 mg JEN

    Janssen-Cilag International N.V.

    Relapsed and Lenalidomide-Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Dexamethason 8 mg GALEN® Tabletten, Privigen 100 mg/ml solution for infusion, teclistamab, JNJ-64407564, Pomalidomide, Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Pomalidomide, Imnovid 1 mg hard capsules, Empliciti 400 mg powder for concentrate for solution for infusion., Empliciti 300 mg powder for concentrate for solution for infusion., Pomalidomide, VELCADE 3.5 mg powder for solution for injection, Privigen 100 mg/ml s

    Janssen-Cilag International N.V.

    Relapsed or Refractory Myeloma

    phase 3 small molecule active

    1 trial

  10. Revlimid 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, VELCADE 3.5 mg powder for solution for injection, DEXAMETHASONE , Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 10 mg hard capsules, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. STELARA 90 mg solution for injection in pre-filled syringe, Guselkumab, STELARA 45 mg solution for injection, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  12. STELARA 90 mg solution for injection in pre-filled syringe, Solution for injection in pre-filled syringe without Ustekinumab 45, Solution for injection in pre-filled syringe without Ustekinumab 90, STELARA 45 mg solution for injection, JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  13. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial

  14. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

    phase 3 small molecule active

    1 trial

  15. Simponi 50 mg solution for injection in pre-filled syringe., Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Simponi 100 mg solution for injection in pre-filled syringe.

    Janssen-Cilag International NV

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  16. Solution for injection in pre-filled syringe without Ustekinumab 90, Solution for injection without Ustekinumab 45, STELARA 45 mg solution for injection, STELARA 90 mg solution for injection in pre-filled syringe, JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  17. Spravato 28 mg nasal spray, solution, Midazolam-ratiopharm® 2 mg/ml orale Lösung, Oral placebo, Intranasal Placebo

    Janssen-Cilag International N.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  18. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. TRIAMCINOLONE , VANCOMYCIN , CEFAZOLIN , BETAMETHASONE , OMEPRAZOLE , JNJ-74765340, JNJ-74765340, DEXAMETHASONE , CEFUROXIME

    Janssen-Cilag International N.V.

    X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene

    phase 3 small molecule active

    1 trial

  20. VELCADE 3.5 mg powder for solution for injection, Cyclophosphamide Tablets 50 mg, JNJ-54767414, Dexamethason 4 mg JENAPHARM®

    Janssen-Cilag International N.V.

    AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

    phase 3 small molecule active

    1 trial

  21. teclistamab, teclistamab, JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. -, MERCAPTOPURINE , -, Film-Coated Tablet without JNJ-77242113, JNJ-77242113, AZATHIOPRINE , METHOTREXATE , JNJ-77242113

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  23. A clinical study to evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 other active

    1 trial

  24. CARBOPLATIN , JNJ-42756493, JNJ-63723283, CISPLATIN , JNJ-42756493, JNJ-63723283, JNJ-42756493

    Janssen-Cilag International N.V.

    Metastatic or Locally Advanced Urothelial Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources